Phenoxybenzamine Versus Doxazosin in PCC Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

134

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Pheochromocytoma
Interventions
DRUG

Phenoxybenzamine

Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)

DRUG

Doxazosin

Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)

Trial Locations (1)

9700 RB

Department of Endocrinology, University Medical Center Groningen, Groningen

All Listed Sponsors
collaborator

Radboud University Medical Center

OTHER

collaborator

UMC Utrecht

OTHER

collaborator

VU University of Amsterdam

OTHER

collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

collaborator

Leiden University Medical Center

OTHER

collaborator

Erasmus Medical Center

OTHER

collaborator

Maastricht University Medical Center

OTHER

collaborator

St. Antonius Hospital

OTHER

collaborator

Medisch Spectrum Twente

OTHER

collaborator

Maxima Medical Center

OTHER

collaborator

Canisius-Wilhelmina Hospital

OTHER

collaborator

Onze Lieve Vrouwe Gasthuis

OTHER

collaborator

Atrium Medical Center

OTHER

collaborator

Isala

OTHER

lead

University Medical Center Groningen

OTHER

NCT01379898 - Phenoxybenzamine Versus Doxazosin in PCC Patients | Biotech Hunter | Biotech Hunter